Compare FLNT & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FLNT | IXHL |
|---|---|---|
| Founded | 2001 | 2001 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Advertising | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.5M | 49.1M |
| IPO Year | N/A | N/A |
| Metric | FLNT | IXHL |
|---|---|---|
| Price | $2.54 | $0.41 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | 51.8K | ★ 26.4M |
| Earning Date | 11-13-2025 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $212,352,000.00 | $12,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.56 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.50 | $0.08 |
| 52 Week High | $3.12 | $2.25 |
| Indicator | FLNT | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 61.61 | 51.98 |
| Support Level | $1.94 | $0.40 |
| Resistance Level | $2.20 | $0.47 |
| Average True Range (ATR) | 0.23 | 0.04 |
| MACD | 0.06 | -0.00 |
| Stochastic Oscillator | 67.39 | 38.26 |
Fluent Inc is a data-driven digital marketing services company. It performs customer acquisition services by operating digital marketing campaigns, through which it connects its advertiser clients with consumers company is seeking to reach. It delivers data and performance-based marketing executions to its clients, such as consumer brands, direct marketers and agencies across a wide range of industries, including Financial Products & Services, Media & Entertainment, Health & Wellness, Staffing & Recruitment and Retail & Consumer.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.